Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	82	130	69	38	121	49
Market Cap Growth	-23.58%	87.08%	83.20%	-68.69%	148.64%	5.47%
Enterprise Value	60	112	81	32	147	92
PE Ratio	28.00	15.62	-4.65	-1.37	-18.55	-2.66
PS Ratio	1.38	1.98	1.46	0.99	1.92	0.89
PB Ratio	2.76	3.87	-6.52	-6.28	-4.48	-0.69
P/FCF Ratio	18.79	-52.64	-2.71	-3.24	-4.52	-2.44
P/OCF Ratio	13.99	-98.52	-2.78	-3.68	-4.64	-2.51
EV/Sales Ratio	1.01	1.70	1.69	0.84	2.34	1.68
EV/EBITDA Ratio	6.22	9.58	-6.77	-1.67	36.61	-10.09
EV/EBIT Ratio	7.13	10.67	-6.20	-1.58	54.19	-8.57
EV/FCF Ratio	13.73	-45.23	-3.15	-2.77	-5.49	-4.59
Debt / Equity Ratio	0.89	0.78	-3.15	-5.55	-2.38	-0.87
Debt / EBITDA Ratio	2.73	2.26	-2.81	-1.73	16.05	-6.70
Debt / FCF Ratio	6.04	-10.65	-1.31	-2.86	-2.41	-3.05
Quick Ratio	0.95	1.09	0.83	1.28	0.47	0.56
Current Ratio	1.38	1.54	1.38	1.86	0.64	0.81
Asset Turnover	0.68	0.80	0.79	0.42	0.85	1.02
Interest Coverage	5.12	5.52	-9.41	-2.87	0.29	-1.42
Return on Equity (ROE)	19.50%	29.70%	151.00%	-881.10%	20.70%	27.20%
Return on Assets (ROA)	7.80%	10.20%	-24.70%	-30.00%	-8.80%	-33.90%
Return on Capital (ROIC)	14.53%	16.96%	-56.99%	-74.59%	7.25%	114.05%
Earnings Yield	8.34%	6.40%	-21.50%	-72.80%	-5.39%	-37.55%
FCF Yield	5.32%	-1.90%	-36.92%	-30.86%	-22.11%	-41.06%
Buyback Yield / Dilution	-27.06%	-70.04%	-9.81%	-51.43%	-96.44%	-0.85%
Total Shareholder Return	-27.06%	-70.04%	-9.81%	-51.43%	-96.44%	-0.85%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).